Table 3.
Study | Year | n | Age | Source (n) | Median Time after HCT, yr | Treated with TBI, % | MetSyn, % | Other |
---|---|---|---|---|---|---|---|---|
Taskinen M et al. [13] | 2000 | 23 | 10-32 | Allo | 10.8 | 78 | 39 | |
Shalitin et al. [16] | 2006 | 91 | 4-32 | Allo (45), auto (46) | 6.2 (mean) | 16 | ND | 27.9% of tested patients with dyslipidemia |
Taskinen M et al. [17] | 2007 | 31 | 7-34 | Allo | 6 | 90 | 39 | 48% developed GH deficiency (75% of individuals with MetSyn) |
Chow EJ et al. [11] | 2010 | 26 | 8-21 | Allo | 6 | 100 | 23 | 38.5% treated with cranial radiation, 50% developed GH deficiency |
Oudin C et al. [15] | 2011 | 60 | 18-41 | Allo (39), auto (21) | 15.4 | 72 | 15 | |
Bajwa R et al. [10] | 2012 | 160 | 5-28 | Allo (99) Auto (70) | 7 | 37 | 7.5 | 17% developed GH deficiency |
Frisk P et al. [12] | 2012 | 18 | 17-37 | Allo (3), auto (15) | 18.2 | 100 | 17 | 39% treated with cranial radiation |
Paris C et al. [18] | 2012 | 69 | 6-25 | Allo (59), auto (10) | 4 | 55 | 32 | Low HDL most common component. Corticosteroid use before or after post-HCT was most significant risk factor for MetSyn. |
Bizzarri C et al. [14] | 2015 | 45 | 13.9 ± 4.8 | Allo (40), auto (5) | 4-6.9 (mean) | 47 | 0 | |
Oudin C et al. [19] | 2015 | 170 | 24.8 ± 5.4 | Allo (124), auto (46) | 14.5 (mean) | 73 | 17 | 9% treated with cranial/craniospinal radiation; GH deficiency associated with increased MetSyn risk |
Higgins K et al. [20] | 2005 | 16 | 25-54 | Allo (13), auto (3) | 6 (mean) | 93 | 25 | Hypertriglyceridemia most common |
Annaloro C et al. [9] | 2008 | 85 | 26-63 | Allo (39), auto (46) | 9 | 78 | 34 | Hypertriglyceridemia most common |
Majhail NS et al. [21] | 2009 | 86 | 21-71 | Allo | 3 | 77 | 49 | Hypertriglyceridemia most common |
McMillen KK et al. [22] | 2014 | 785 | 18-74 | Allo | 48 | 34% pre-HCT 40% modified MetSyn at 1 yr |
Hypertriglyceridemia most common |
Allo indicates allogeneic; auto, autologous; ND, not defined; GH, growth hormone.